Liraglutide Injection is used for glycemic control in adults with type 2 diabetes mellitus in patients who have poor glycemic control despite treatment with metformin or sulfonylurea alone at the maximum tolerable dose, and can be used in combination with metformin or sulfonylurea. Liraglutide is a GLP-1 analog that can be used clinically for glycemic control in adults with type 2 diabetes mellitus in patients whose blood glucose remains poorly controlled after treatment with metformin and sulfonylureas alone. It can be used in combination with metformin without changing the dose of metformin. It can also be used in combination with sulfonylureas, in which case a reduction in the dose of sulfonylureas should be considered to reduce the risk of hypoglycemia The drug requires careful monitoring of blood glucose levels during its application. Common adverse reactions include gastrointestinal disturbances such as vomiting, constipation, abdominal pain, dyspepsia, etc. Side effects such as hypoglycemia and allergic reactions may also occur. This product should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Liraglutide medication needs to be used appropriately under the supervision of a doctor.